Introduction

The Consortium activities are driven by members interacting frequently, both at in-person meetings, teleconferences, and in the discussion forum.  Working Groups have been formed to help drive areas believed to be key to advancing our knowledge of mantle cell lymphoma.  These groups include:  MCLC Executive Committee, MCLC Website Working Group, MCLC Cell Bank Working Group, MCLC Clinical Trials Working Group, and an MCLC Pathology Core Working Group.  MCLC Members are eligible to join a working group.  If you are interested in joining one of the working groups, please contact the Working Group Chair or the Lymphoma Research Foundation directly at mclc@lymphoma.org.

MCLC Working Groups 

Mantle Cell Lymphoma Consortium (MCLC) Executive Committee

• Michael Williams, MD - Chair (University of Virginia)
• Joseph Connors, MD, FRCPC (British Columbia Cancer Agency)
• Martin Dreyling, MD, PD (University of Munich)
• John Leonard, MD (Weill Medical College of Cornell University)
• Owen O'Connor, MD, PhD (Memorial Sloan Kettering Cancer Center)

MCLC Website Working Group

• Joseph Connors, MD, FRCPC - Chair (British Columbia Cancer Agency)
• Elliot Epner, MD (Oregon Health & Sciences University)
• Richard Ford, MD, PhD (MD Anderson Cancer Center)
• Randy Gascoyne, MD (British Columbia Cancer Agency)
• Jonathan Said, MD (University of California Los Angeles)

MCLC Cell Bank Working Group

• Owen O'Connor, MD, PhD - Chair (Memorial Sloan Kettering Cancer Center)
• W. C. Chan, MD (University of Nebraska)
• Richard Ford, MD (MD Anderson Cancer Center)
• Eduardo Sotomayor, MD (H. Lee Moffitt Cancer Center)

MCLC Clinical Trials Working Group

• John Leonard, MD - Co-Chair (Cornell University)
• Martin Dreyling, MD - Co-Chair (University of Munich)
• Bruce Cheson, MD (Georgetown University)
• Ajay Gopal, MD (Fred Hutchinson Cancer Center)
• Issa Khouri, MD (MD Anderson Cancer Center) 
• Julie Vose, MD (University of Nebraska)
• Thomas Witzig, MD (Mayo Clinic)

MCLC Pathology Core

• Michael Williams, MD - Chair (University of Virginia)
• Randy Gascoyne, MD (British Columbia Cancer Agency)
• Mark Raffeld, MD (National Cancer Institute, NIH)